chufangao/CTO huggingface dataset:
Clinical trial NCT04503668: Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients
Official title: Phase III Randomized Control Trial Investigating Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Patients With Gynecologic Malignancies Receiving Every 3-week Carboplatin and Paclitaxel Chemotherapy
Sponsor: University of Michigan Rogel Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Lack of Patient Population
Enrollment: 62.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-28
Primary completion date: 2024-01-03
Completion date: 2024-03-11
Plan to share individual participant data: NO
Clinical trial NCT04390113: Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)
Official title: Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant (HCT)
Sponsor: AlloVir (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Study discontinued as DSMB determined it was futile. No safety concerns were noted.
Enrollment: 97.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-18
Primary completion date: 2024-01-30
Completion date: 2024-01-30
Limitations and caveats: AlloVir decided to discontinue the trial on 22-Dec-2023 following a pre-planned DSMB futility analysis concluding the study was unlikely to meet its primary endpoint; no safety concerns were identified.
Plan to share individual participant data: NO
Clinical trial NCT01737827: Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma.
Official title: A Phase II, Open Label, Single Arm, Multicenter Study of INC280 Administered Orally in Adults With Advanced Hepatocellular Carcinoma
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study recruitment was ended due to difficulties in identifying subjects who meet the eligibility criteria and therefore the study never reached its planned sample size per protocol. The study termination was not due to any safety concerns.
Enrollment: 38.0 (ACTUAL)
Number of arms: 1.0
Start date: 2013-03-25
Primary completion date: 2023-04-24
Completion date: 2023-05-24
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Clinical trial NCT04737187: Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients
Official title: An Open-label, Randomized, Phase III Study Comparing Trifluridine/Tipiracil in Combination With Bevacizumab to Trifluridine/Tipiracil Monotherapy in Patients With Refractory Metastatic Colorectal Cancer (SUNLIGHT Study)
Acronym: SUNLIGHT
Sponsor: Taiho Oncology, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 492.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-25
Primary completion date: 2022-07-19
Completion date: 2023-09-12
Baseline population: Full Analysis Set (FAS): all participants to whom a therapeutic unit was randomly assigned using Interactive Web Response System (IWRS). Participants were analyzed in the arm they were assigned by randomization.
Plan to share individual participant data: NO
Clinical trial NCT04409223: Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib
Official title: A Phase III, Open Label, Randomised，Controlled, Multi-centre Study to Assess the Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib
Sponsor: Jiangsu HengRui Medicine Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: R\&D strategy adjustment
Enrollment: 185.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-12
Primary completion date: 2022-03-25
Completion date: 2022-03-25
Clinical trial NCT03929744: A Study of LY3502970 in Healthy Participants
Official title: A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3502970 in Healthy Subjects
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 133.0 (ACTUAL)
Number of arms: 9.0
Start date: 2019-06-12
Primary completion date: 2020-11-02
Completion date: 2020-11-02
Plan to share individual participant data: NO
Clinical trial NCT04209114: A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer
Official title: A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus Bempegaldesleukin (NKTR-214), Versus Nivolumab Alone Versus Standard of Care in Participants With Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 114.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-02-05
Primary completion date: 2023-06-07
Completion date: 2023-06-07
Limitations and caveats: BMS and Nektar Therapeutics jointly decided to terminate the clinical development program for bempegaldesleukin (NKTR-214) in combination with nivolumab. Discontinued survival follow-up and the stopping of submission of local labs to vendors, imaging to the BICR vendor, and PROs have resulted in confounded and incomplete trial results.
Plan to share individual participant data: YES
IPD sharing description: Individual patient level data from this study may be shared with qualified researchers, upon request, following the timelines and process detailed on https://www.bms.com/researchers-and-partners/independent-research/data-sharing-request-process.html
Clinical trial NCT05330689: How Does Platelet Dose Impact Clinical Outcomes After PRP Treatment?
Official title: How Does Platelet Dose Impact Clinical Outcomes After PRP Treatment?
Sponsor: Vanderbilt University Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Funding for study equipment
Enrollment: 0.0 (ACTUAL)
Number of arms: 5.0
Start date: 2022-03-06
Primary completion date: 2022-09-07
Completion date: 2022-09-07
Plan to share individual participant data: NO
Clinical trial NCT03228836: Efficacy and Safety Evaluation of IBI308 in Patients With Extranodal NK/T Cell Lymphoma Patients
Official title: Efficacy and Safety Evaluation of IBI308 in Patients With Relapsed/Refractory Extranodal NK/T Cell Lymphoma, Nasal Type: a Multicenter, Single Arm, Phase 2 Study (ORIENT-4)
Acronym: ORIENT-4
Sponsor: Innovent Biologics (Suzhou) Co. Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 28.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-08-23
Primary completion date: 2020-02-28
Completion date: 2020-02-28
Plan to share individual participant data: NO
Clinical trial NCT04691141: A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS)
Official title: A Phase I/II, Open-label Study to Investigate the Pharmacokinetics, Safety, and Efficacyof ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS) Patients After Failure of Hypomethylating Agent (HMA)-Based Therapy
Acronym: HATCH
Sponsor: Antengene Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The study was stopped early because the sponsor decided to change the study-drug development strategy
Enrollment: 15.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-02-23
Primary completion date: 2023-09-19
Completion date: 2023-09-19
Clinical trial NCT03420781: A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03
Official title: A 46-week, Double-blind, Placebo-controlled, Phase 3 Study With a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis
Sponsor: Allergan (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The Relamorelin program is being terminated solely based on a business decision.
Enrollment: 467.0 (ACTUAL)
Number of arms: 5.0
Start date: 2018-01-24
Primary completion date: 2020-10-30
Completion date: 2020-10-30
Baseline population: ITT Population included all participants who entered the 40-week treatment period.
Clinical trial NCT03345160: Peanut Oral Immunotherapy in Children: IMPACT Follow Up Study
Official title: Open Label Peanut Oral Immunotherapy in Children: IMPACT Follow Up Study
Sponsor: Johns Hopkins University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 7.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-04-27
Primary completion date: 2020-10-07
Completion date: 2020-10-07
Plan to share individual participant data: NO
IPD sharing description: Data will not be shared
Clinical trial NCT03206918: Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Official title: A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Safety and Efficacy of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Sponsor: BeiGene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 91.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-03-09
Primary completion date: 2018-06-15
Completion date: 2020-09-10
Baseline population: Safety Analysis Set: All participants who received any dose of study drug.
Plan to share individual participant data: YES
Clinical trial NCT03828747: A Study of Semorinemab in Patients With Moderate Alzheimer's Disease
Official title: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients With Moderate Alzheimer's Disease
Sponsor: Genentech, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 272.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-25
Primary completion date: 2021-07-20
Completion date: 2023-08-30
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)
Clinical trial NCT03641248: Bioavailability and Pharmacokinetic Measures of H. Procumbens Extract
Official title: Study to Establish the Bioavailability and Pharmacokinetic Measures of H. Procumbens Extract in Humans
Sponsor: University of Missouri-Columbia (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Recruitment was not possible due to COVID19.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-05-01
Primary completion date: 2021-07-31
Completion date: 2021-08-31
Plan to share individual participant data: NO
Clinical trial NCT05246280: Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA
Official title: Evaluation of Tc 99m Tilmanocept Imaging for the Early Prediction of Anti-TNFα Therapy Response in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)
Sponsor: Navidea Biopharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Sponsor Decision
Enrollment: 196.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-03-02
Primary completion date: 2024-07-09
Completion date: 2024-07-09
Plan to share individual participant data: NO
Clinical trial NCT03758170: High-Dose Steroid for Knee Arthroplasty
Official title: High-Dose Steroid for Total Knee Arthroplasty - A Randomized Doubleblinded Controlled Trial
Sponsor: Copenhagen University Hospital, Hvidovre (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 160.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-29
Primary completion date: 2022-02-01
Completion date: 2022-02-01
Plan to share individual participant data: YES
IPD sharing description: Data will be available upon reasonable request
IPD time frame: From 1 year after last included patient, and onto 4 years after end of trial.
IPD access criteria: Upon reasonable request to the corresponding author
Clinical trial NCT03866538: Budesonide in Patients With Immune Mediated Enteropathies
Official title: Open-label Withdrawal Trial of Budesonide in Patients With Immune Mediated Enteropathies
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Study recruitment was difficult and not acheived
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-09-10
Primary completion date: 2021-10-19
Completion date: 2021-10-19
Baseline population: Study was terminated due to recruitment being difficult and not achieved
Limitations and caveats: Study was terminated due to recruitment being difficult and not achieved.
Plan to share individual participant data: NO
Clinical trial NCT03121677: Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma
Official title: Pilot Study of a Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Vaccine manufacturing has been suspended
Enrollment: 4.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-10-16
Primary completion date: 2020-09-24
Completion date: 2023-08-07
Plan to share individual participant data: NO
Clinical trial NCT02933073: Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma
Official title: A Phase I Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma
Sponsor: UConn Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Study recruitment is temporary on hold by the sponsor due to patient recruitment challenges and the ongoing review of the investigational adjuvant.
Enrollment: 8.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-11-30
Primary completion date: 2022-08-31
Completion date: 2022-08-31
Plan to share individual participant data: NO
Clinical trial NCT04829799: Effect of Intracameral Phenylephrine/Ketorolac on Intraoperative Pain
Official title: Effect of Intracameral Phenylephrine/Ketorolac on Intraoperative Pain
Sponsor: University of Florida (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Per study team, the study will not proceed
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-02-28
Primary completion date: 2023-08-31
Completion date: 2023-08-31
Plan to share individual participant data: NO
Clinical trial NCT04021017: PRE-GAiN Bone Health Pilot Study
Official title: PRE-GAIN Bone Health Pilot Study - Physiologic Replacement of EstroGen for Adolescent Females With AnorexIa Nervosa for Bone Health Pilot Study
Acronym: PRE-GAiN
Sponsor: University of Saskatchewan (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: PI Workload
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-21
Primary completion date: 2022-12-13
Completion date: 2022-12-13
Plan to share individual participant data: NO
Clinical trial NCT03685253: Nicotinamide Riboside for Diabetic Neuropathy
Official title: Nicotinamide Riboside in Diabetic Polyneuropathy
Acronym: NiRiD
Sponsor: University of Maryland, Baltimore (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: SUSPENDED 
Why stopped: pilot component of study completed
Enrollment: 54.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2019-01-24
Primary completion date: 2022-10-01
Completion date: 2024-10-01
Plan to share individual participant data: NO
Clinical trial NCT02802163: Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat
Official title: Phase I-II Study of Carfilzomib, Lenalidomide, Dexamethasone, and Panobinostat, Ca-R-Pa-Diem, as Induction Therapy for Newly Diagnosed, Untreated, Transplant-Eligible, Multiple Myeloma Patients
Sponsor: H. Lee Moffitt Cancer Center and Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: study drug unavailable
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-06-30
Primary completion date: 2020-09-30
Completion date: 2020-12-31
Clinical trial NCT04458311: Abiraterone Acetate in Combination With Tildrakizumab
Official title: ACTION: Phase I/II Trial of Abiraterone Acetate in Combination With Tildrakizumab (Anti-IL23 Targeting Monoclonal Antibody) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Acronym: ACTIon
Sponsor: Institute of Cancer Research, United Kingdom (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Funder decided that response outcomes to date did not support continuation of the study.
Enrollment: 13.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-01
Primary completion date: 2023-04-01
Completion date: 2023-11-15
Clinical trial NCT05486195: A Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects Including an Assessment of Receptor Occupancy and Food Effect
Official title: A First-in-Human, Randomized, Placebo-controlled, Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects Including Receptor Occupancy Measurements After Single Dose of SDI-118 and an Assessment of Food Effect
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 32.0 (ACTUAL)
Number of arms: 7.0
Start date: 2019-03-14
Primary completion date: 2019-07-29
Completion date: 2020-03-11
Plan to share individual participant data: NO
Clinical trial NCT02655523: A Comparison of Dexamethasone and Triamcinolone for Ultrasound-guided Occipital C2 Nerve Blocks
Official title: A Comparison of Dexamethasone and Triamcinolone in Combination With Bupivacaine for Ultrasound-guided Occipital C2 Nerve Blocks: A Randomized Controlled Trial
Sponsor: Northwestern University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: lack of recruitment
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2015-12-31
Primary completion date: 2022-06-30
Completion date: 2022-06-30
Plan to share individual participant data: NO
Clinical trial NCT03711929: LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye
Official title: LUMINA: A Phase III, Multicenter, Sham-Controlled, Randomized, Double-Masked Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye.
Sponsor: Santen Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Business decision
Enrollment: 145.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-11-19
Primary completion date: 2022-06-14
Completion date: 2022-06-14
Clinical trial NCT04347902: Lipid Emulsions and Liver Function - Results After 5 Years.
Official title: Intravenous Lipid Emulsions and Liver Function in Adult Chronic Intestinal Failure Patients: New Results After 5 Years.
Acronym: 5ylipids
Sponsor: Stanley Dudrick's Memorial Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 65.0 (ACTUAL)
Number of arms: 3.0
Start date: 2016-01-31
Primary completion date: 2020-03-31
Completion date: 2020-04-30
Plan to share individual participant data: NO
Clinical trial NCT02425891: A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)
Official title: A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 902.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-06-23
Primary completion date: 2020-04-14
Completion date: 2021-08-31
Clinical trial NCT03968159: Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
Official title: Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment (ACP-103-054/059)
Sponsor: ACADIA Pharmaceuticals Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 298.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-04-25
Primary completion date: 2020-04-30
Completion date: 2020-05-29
Limitations and caveats: In March 2020, recruitment of new patients was paused due to the emerging coronavirus disease 2019 (COVID-19) pandemic. At that point in time, about half of the planned patients had been randomized. The Sponsor decided to combine this trial with the identically designed trial ACP-103-054, with a prespecified combined statistical analysis plan. As a result, both trials were closed and proceeded with database lock and statistical analysis of the combined data. No further patients were enrolled.
Plan to share individual participant data: NO
Clinical trial NCT03032614: Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
Official title: Phase II Clinical Trial on the Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients With Homologous Recombination Deficiency
Sponsor: The University of Texas Health Science Center at San Antonio (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Lack of funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-09-30
Primary completion date: 2019-03-31
Completion date: 2020-04-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03202667: Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study
Official title: Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study
Acronym: SANDx
Sponsor: University Hospital, Basel, Switzerland (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 17.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-12-15
Primary completion date: 2021-08-26
Completion date: 2021-12-06
Plan to share individual participant data: NO